Skip to content
MarketScale
‹ Back to IndustriesHealthcare

What CarePass From CVS Signals to the Market

In the 1970s, the Veterans Administration (now called the VA) mailed prescription medications to regional customers. This was actually far ahead of the curve. It was not until the 1990s that mail-order pharmacy services were common among the general population. Until recent years, people had to go to a physical pharmacy location for medications and…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

In the 1970s, the Veterans Administration (now called the VA) mailed prescription medications to regional customers. This was actually far ahead of the curve. It was not until the 1990s that mail-order pharmacy services were common among the general population.

Until recent years, people had to go to a physical pharmacy location for medications and medical supplies. With the rise of overnight, home-delivery services offering anything from beauty products to groceries, traditional pharmacies are adapting to meet consumer preferences.

Modernizing Pharmacy Delivery Services

CVS Pharmacy, for instance, has expanded its membership and rewards programs by creating the new program CarePass. For $5 a month or $48 annually, CarePass participants can have medications delivered- as well as many other items found in its retail locations. This differs from mail-order prescriptions services, which only sell medications and have no physical retail locations. Other perks, like access to a secure 24/7 helpline, are offered.

This new program by CVS is competitive with home-delivery retail giants like Amazon Prime. For instance, because CVS has physical brick-and-mortar stores across the nation, the program can include perks like free sports physicals and discounts that apply in-person as well as online. Because CVS is also a known and trusted brand even by older generations, it also has a customer base which online-only services may have trouble reaching.

Beyond Pharmacies: The Omni-Channel Retail Trend

Although CVS’s new program is unique among pharmacies, many other retailers have joined the store to door trend. Called “omnichannel” retailing, well-known retailers with storefronts are now using social media, their websites, and apps to sell merchandise that can be delivered to customers’ homes. Stores are also offering “pick-up” services where customers can place their orders online and pick up the complete order instead of having to browse the physical location themselves.

Programs that utilize multiple channels, as well as mixed shopping and delivery services, are likely to grow as younger generations of consumers embrace them. For example, studies show that Gen Z and Millennial consumers are increasingly comfortable with eCommerce and favor streamlined, convenient shopping experiences.

Examples of Rising Store to Door Programs

Two industries where delivery services are increasing are restaurants and grocery stores. There has been a 20-percent increase in restaurant delivery in the past five years, and even fast-food chains have begun to offer delivery through third-party service providers. Grocery stores and superstores, like Walmart, are also adapting and developing models to meet the new customer-preference for delivery.

Walmart, for instance, is now offering Delivery Unlimited, a service similar to Amazon Prime. For $98 annually or $12.95 a month, consumers can sign up for the program and have Walmart deliver groceries to their front door. Target offers a similar program called Shipt. Other retailers, like Costco and Aldi, partner with a service called Instacart for delivery services.

Currently, consumer habits still show a need for physical store locations. People are still shopping both online and in person. However, retailers who use multiple channels and methods offer customers an experience that seems to be paying off.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended AstraZeneca and Daiichi Sankyo’s Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly is investing $6.5 billion in a Houston manufacturing facility set to open around 2030, primarily to scale production of Foundayo, its oral GLP-1 treatment. The project signals a broader shift in U.S. pharmaceutical manufacturing reshoring and underscores the supply chain challenge of forecasting demand and building capacity years in advance for breakthrough therapeutics.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain: Lilly's CEO noted that one-third of new GLP-1 pill patients are now choosing Foundayo, illustrating fast-moving market share shifts that complicate production planning years in advance
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

Waiting for perfectly clean data is stalling healthcare AI, not protecting it

Healthcare organizations often delay AI initiatives waiting for perfectly clean data, but this assumption no longer holds: reliable subsets and synthetic data allow projects to start now while data work continues in parallel. Success requires starting with business outcomes rather than technology capabilities, and embedding governance in product strategy before implementation, not after.

  • 01Waiting for 100% clean data is effectively a decision never to start; hospital AI projects can begin on reliable data subsets while quality work continues in parallel.
  • 02Frame AI decisions around business outcomes (revenue growth, cost reduction, competitive advantage, new products, or ecosystem influence) rather than asking what AI can do.
  • 03Governance should be part of product strategy before design or purchase, especially as agentic AI takes actions—such as handling many revenue-cycle denials—while routing the rest to humans.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512